TCV vaccines

Programme experience indicates that TCV campaigns can achieve substantial uptake, although reported coverage varied considerably across the settings reviewed. Facilitators included school-based delivery, community outreach, government leadership, partner coordination and engagement of trusted local influencers. Reported barriers included limited awareness, access constraints, fear of adverse effects, rumours and personal or philosophical objections. In the SAGE Evidence-to-Recommendation assessment, TCV-specific hesitancy and public resistance were rarely identified as major barriers; stakeholder concerns focused more strongly on financing, competing immunization priorities, programme fit and the strength of disease-burden evidence. Acceptability of a booster dose has not been systematically assessed.^{Go to footnote 11, Go to footnote 22, Go to footnote 33}